In addition, retrospective and prospective studies in breast cancer patients revealed that loss of MCJ in primary tumors correlates with poor responses to chemotherapy, but not with responses to hormone therapy (which is not affected by ABC transporters)29. This evidence concerns the gene ABCG2 and breast carcinoma.